# Blood banks
# Pathologists and pathology laboratories
# Distributors of IVD products
# Research institutes
# Hospitals and clinics
# Healthcare institutions
# Group purchasing organizations (GPOs)
# Market research and consulting firms
The report "Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes) - Global Forecast to 2023", The global hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, at a CAGR of 4.9% during the forecast period (2018–2023).
Increasing number of blood transfusions & donations, high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations are the major factors driving this market.
Research Methodology Used:
Top-down and bottom-up approaches were used to validate the size of the global hepatitis test solution/diagnosis market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research, and their market revenues were determined through primary and secondary research.
Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases.
In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.
Download PDF [email protected]
The hepatitis C segment is expected to grow at the highest rate in the next five years
On the basis of disease type, the market is segmented into hepatitis B, hepatitis C, and other hepatitis disease. The hepatitis C segment is projected to grow at the highest CAGR during the forecast period. This growth is primarily attributed to the increasing incidence of HCV infections and limited vaccination coverage.
The ELISA segment is expected to hold the largest market share during the forecast period
On the basis of technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies. In 2018, the ELISA is expected to account for the largest market share, by technology. The wide acceptance of this test in clinical practices to diagnose hepatitis is the main factor driving this market.
North America is expected to dominate the hepatitis test solution/diagnosis market in 2018
North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. The large share of the North America region is primarily attributed to factors such as the rising adoption of advanced technologies, developed healthcare systems in the US and Canada, and the presence of a large number of leading national clinical laboratories.
The APAC region is expected to grow at the highest CAGR over the next five years. The growth of the hepatitis test solution/diagnosis market in this region is driven by the modernization of healthcare infrastructure, high burden of hepatitis infections, increased healthcare spending by a larger population base, and the rising penetration of cutting-edge clinical laboratory technologies.
The key players operating in this market include Abbott Laboratories (US), Roche (Switzerland), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), bioMérieux (France), Danaher (US), and Grifols (Spain).
Request Sample [email protected]
Collaborations, agreements, and partnerships remain at the center of the strategic growth initiatives adopted by most of the key players in the global hepatitis test solution/diagnosis market. Companies such as Abbott Laboratories, Roche Diagnostics, Bio-Rad, DiaSorin, Danaher, and Grifols have been focusing on this inorganic strategy to enhance their market presence. Players also adopted product launches, product approval, and acquisition as growth strategies.